In vitro inhibition of hepadnavirus polymerases by the triphosphates of BMS-200475 and lobucavir.
about
The Molecular and Structural Basis of HBV-resistance to Nucleos(t)ide AnalogsHepatitis B virus reverse transcriptase: diverse functions as classical and emerging targets for antiviral interventionDirect acting antivirals for the treatment of chronic viral hepatitisPotent efficacy of entecavir (BMS-200475) in a duck model of hepatitis B virus replication.Mechanistic characterization and molecular modeling of hepatitis B virus polymerase resistance to entecavirClinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine.Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions presentCharacterization of the antiviral effect of 2',3'-dideoxy-2', 3'-didehydro-beta-L-5-fluorocytidine in the duck hepatitis B virus infection model.Reverse transcriptase in motion: conformational dynamics of enzyme-substrate interactions.Antiviral treatment of chronic hepatitis B virus (HBV) infectionsSafety and efficacy of entecavir for the treatment of chronic hepatitis B.Current Antiviral Therapy of Chronic Hepatitis B: Efficacy and SafetyChanges in Mitochondrial Toxicity in Peripheral Blood Mononuclear Cells During Four-Year Administration of Entecavir Monotherapy in Chinese Patients with Chronic Hepatitis BGenetic Evidence for Genotoxic Effect of Entecavir, an Anti-Hepatitis B Virus Nucleotide Analog.4'-modified nucleoside analogs: potent inhibitors active against entecavir-resistant hepatitis B virus.Carbonyl J acid derivatives block protein priming of hepadnaviral P protein and DNA-dependent DNA synthesis activity of hepadnaviral nucleocapsids.Hepatitis B virus reverse transcriptase - Target of current antiviral therapy and future drug development.Antiviral therapies: focus on hepatitis B reverse transcriptaseInhibition of hepadnavirus reverse transcriptase-epsilon RNA interaction by porphyrin compoundsOptimized combination therapies with adefovir dipivoxil (ADV) and lamivudine, telbivudine, or entecavir may be effective for chronic hepatitis B patients with a suboptimal response to ADV monotherapy.Effects of mutations of the initiation nucleotides on hepatitis C virus RNA replication in the cellNoncompetitive inhibition of hepatitis B virus reverse transcriptase protein priming and DNA synthesis by the nucleoside analog clevudine.Efficacy of the carbocyclic 2'-deoxyguanosine nucleoside BMS-200475 in the woodchuck model of hepatitis B virus infection.Kinetic analysis of wild-type and YMDD mutant hepatitis B virus polymerases and effects of deoxyribonucleotide concentrations on polymerase activity.Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro.Clinical characteristics of patients with chronic hepatitis B who developed genotypic resistance to entecavir: Real-life experience.Combinations of adefovir with nucleoside analogs produce additive antiviral effects against hepatitis B virus in vitro.Inhibition of hepatitis B virus polymerase by entecavir.In vitro characterization of the anti-hepatitis B virus activity and cross-resistance profile of 2',3'-dideoxy-3'-fluoroguanosine.Delayed chain termination protects the anti-hepatitis B virus drug entecavir from excision by HIV-1 reverse transcriptase.Entecavir for treatment of hepatitis B virus displays no in vitro mitochondrial toxicity or DNA polymerase gamma inhibition.Profound antiviral effect of oral administration of MIV-210 on chronic hepadnaviral infection in a woodchuck model of hepatitis BBaracle® vs Baraclude® for 48 weeks in patients with treatment-naïve chronic hepatitis B: a comparison of efficacy and safety.HIV-1 with HBV-associated Q151M substitution in RT becomes highly susceptible to entecavir: structural insights into HBV-RT inhibition by entecavir.
P2860
Q26781795-A30AE606-F39D-4D91-AD50-669B9B6195B9Q27013849-D18B6123-F2A5-4DD6-94FF-E64696F1501CQ27022216-6BEE4708-92E4-4B99-AB31-8D2F6B41157AQ28366818-633BC5E4-B919-4A83-8D9F-B7B2AE01404EQ28748931-B42ED766-5663-4B3F-A98A-42D442B8A7CFQ33206221-8D979F97-3A42-4A1E-8C7F-D6C76337260AQ33267067-20C7F9EF-4646-42F7-ABAE-9E6211459655Q33978482-9D71C8A9-053A-4378-ABFC-A1E4A1F3A97CQ34092798-2716BB4B-501C-4443-A97D-D4C4996976F9Q34223779-0F2A51A1-949E-4ECA-A888-81A1F4376250Q35026611-73887C7C-0CE9-4EF0-BC00-8443FA1FF4FDQ35535861-0CEB73B5-77AB-4031-AB43-2BE4C0F476A8Q35891653-3F08C38C-6C42-4A58-822E-61F0A5354CA5Q35901801-1D9F9398-B488-4CB3-A389-0DB39264D7ADQ36108952-7FFB2AE1-AFCB-48A5-931B-C45D7E22BF45Q36246202-81CC5FC9-F2CC-4121-8281-5754F3FE69DEQ36264766-61B8B97A-7CEB-4038-9D8F-904754409317Q36467514-30FE3826-38A8-47AB-A45B-71EC02BD48CEQ36483826-3545D7BA-7DC8-45BB-AAC6-E49A69704974Q36492959-300D5CD5-FB22-4A50-AE99-64F692AA0F70Q37009852-3B3BAA14-E335-4CDD-B887-4C95913F20BEQ37124000-37A45A83-2B06-493C-882F-173F7E4027F2Q39559680-DC1A79A5-3CA9-41F2-9148-C575BC058AF0Q39651471-CC3E525D-DCEC-4D1E-B248-6DAFA06175CDQ39652624-291C78E7-169B-4C7D-A92A-B5418ACD5D4FQ40058881-18342AD7-8ED9-4573-AA93-84009B6B5831Q40164099-F63E9DBC-CFFA-4AC0-A2AC-69C9DB87FB51Q40176633-C07E879A-BA0F-4471-9D40-828BE0C9E5E6Q40312810-8C4C6B93-3AF4-4476-8667-85BC8656D7BEQ41503130-E5E6BD30-90F2-4D9E-A8ED-0AA34CD664AAQ41883516-940C71AE-EDAF-4325-A730-B20FCFF39B15Q42004056-96C87CD5-6448-4F32-9E2C-7C8C5011EA53Q47151413-8C1DB095-B6B4-4FDC-AC88-AEB769A01231Q47548606-48470EC5-8FA6-4365-B422-6181A3300BE5
P2860
In vitro inhibition of hepadnavirus polymerases by the triphosphates of BMS-200475 and lobucavir.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
1998年论文
@zh
1998年论文
@zh-cn
name
In vitro inhibition of hepadna ...... s of BMS-200475 and lobucavir.
@en
In vitro inhibition of hepadna ...... s of BMS-200475 and lobucavir.
@nl
type
label
In vitro inhibition of hepadna ...... s of BMS-200475 and lobucavir.
@en
In vitro inhibition of hepadna ...... s of BMS-200475 and lobucavir.
@nl
prefLabel
In vitro inhibition of hepadna ...... s of BMS-200475 and lobucavir.
@en
In vitro inhibition of hepadna ...... s of BMS-200475 and lobucavir.
@nl
P2093
P2860
P356
P1476
In vitro inhibition of hepadna ...... es of BMS-200475 and lobucavir
@en
P2093
D N Standring
R J Colonno
R K Hamatake
P2860
P304
P356
10.1128/AAC.42.12.3200
P407
P577
1998-12-01T00:00:00Z